Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with dismal
prognosis, projected to be the second cause of cancer-related deaths worldwide by
2030 [
[1]
]. Most of the patients will present already a locally advanced or metastatic disease
at diagnosis and systemic chemotherapy remains their main therapeutical option [
[2]
]. In firstline, not only the Folfirinox regimen (5 fluorouracil (5FU), oxaliplatin,
irinotecan and leucovorin) but also the combination of gemcitabine and nab-paclitaxel
(nanoparticle albumin-bound paclitaxel) have demonstrated their superiority in survival
over gemcitabine [
[3]
,
[4]
]. However, the median overall survival is less than a year, with limited therapeutic
options in further lines.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States.Cancer Res. 1 juin 2014; 74: 2913-2921
- Pancreatic cancer.Lancet. 27 juin 2020; 395: 2008-2020
- FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.N Engl J Med. 12 mai 2011; 364: 1817-1825
- Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med. 31 oct 2013; 369: 1691-1703
- Whole genomes redefine the mutational landscape of pancreatic cancer.Nature. févr 2015; 518: 495-501
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.Nat Commun. 9 avr 2015; 6: 6744
- Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the Know Your Tumor registry trial.Lancet Oncol. avr 2020; 21: 508-518
- Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.J Clin Orthod. 20 janv 2021; 39 (265-265)
- The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing.Clin Cancer Res. 1 janv 2016; 22: 259-267
- Stage 4 pancreatic adenocarcinoma harbouring an FGFR2-TACC2 fusion mutation with complete response to erdafitinib a pan-fibroblastic growth factor receptor inhibitor.BMJ Case Reports CP. 1 sept 2021; 14: e244271
- Non-smoking-associated lung cancer: a distinct entity in terms of tumor biology, patient characteristics and impact of hereditary cancer predisposition.Cancers (Basel). 10 févr 2019; 11: E204
- Effect of FGFR2 alterations on survival in patients receiving systemic chemotherapy for intrahepatic cholangiocarcinoma.J Clin Orthod. 20 janv 2021; 39 (303-303)
- Incidence of FGFR2 amplification and FGFR2 fusion in patients with metastatic cancer using clinical sequencing. Wu G, éditeur.J Oncol. 18 mars 2022; 20229714570
Article info
Publication history
Published online: October 13, 2022
Accepted:
September 14,
2022
Received:
September 11,
2022
Identification
Copyright
© 2022 Elsevier Ltd. All rights reserved.
